Follow

Correction: Eevia Health’s share issue in connection to listing on Spotlight Stock Market subscribed over 400 percent

17 June 2021 - 17:57

This is a correction to earlier press release today, which stated that the equity issue was over-subscribed by over 400%. The correct is subscribed by over 400%. Also in one media channel the MAR label was omitted by mistake in the Press release itself.

Eevia Health Plc (“Eevia”), a fast-growing functional foods company, today announces that the new share issue of approximately SEK 26.2 million prior to the planned listing on Spotlight Stock Market, was heavily oversubscribed. Subscriptions from over 3,500 investor accounts for a total subscription value of SEK 109.0 million means that the share issue was subscribed 4.16 times (or 416%). 

The Offering comprised 3,445,000 shares in Eevia and the subscription price amounted to SEK 7.6 per share, meaning that the Company will receive gross proceeds of SEK 26.2 million, and after deduction of issue costs of SEK 2.2 million, net proceeds of SEK 24.0 million. Eevia has added approximately 700 new shareholders through the Offering. The first day of trading on Spotlight Stock Market is scheduled for June 29, 2021. 

Stein Ulve, CEO and Founder Eevia Health comments:

“I am overwhelmed to see the great interest for investing in the growth of our company.This listing is an important step in our long-term journey of building Eevia Health. Today, I thank existing as well as new shareholders for the trust and for supporting us in making the world healthier. Unfortunately, we were not able to allocate shares to all subscribers – to those who did not receive allotment, I wish to welcome you to become shareholders on the 29th of June, when trading in Eevia Health commences on Spotlight Stock Market.”

Following the completion of the Offering, the number of shares in Eevia Health increases from 10,506,500 to 13,961,500 corresponding to a dilution of approximately 24,7 percent. The Offering was covered by subscription commitments amounting to 58 percent of the issue volume, corresponding to SEK 15.2 million. Subscription commitments were entered into by Consensus Asset Management, Polynom Investment and Modelio Equity amongst others.

Advisors
Partner Fondkommission is financial advisor and issuing agent in Sweden in relation to the Offering. OP Bank is issuing agent in Finland in relation to the Offering. 

For more information, please contact: 
 

Stein Ulve, CEO                                 Kim Nurmi-Aro, CFO

[email protected]               [email protected]

Telephone: +358 400 22 5967            +358 504 44 0717

This disclosure contains information that EEVIA HEALTH PLC is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on June 17, 2021.

About Eevia

Eevia was founded in 2017 with the mission to address global health problems through the sustainable production and distribution of bioactive plant extracts, which have scientifically documented health benefits. Through utilization of raw material sources, often under-utilized raw materials abundantly available in the Nordic forests, and sometimes inexpensive byproducts from food and woodindustries, Eevia manufactures and markets organically certified nutraceutical ingredients. The products are targeted against immune health, low-grade inflammation, eye and brain health problems and metabolic disorders. The increasing health awareness among consumers, combined with the increased focus on sustainable business models, constitute strong and significant macro-trends. Eevia stands well equipped to capitalize from these trends, resulting in an accelerating growth trajectory.

Eevia is headquartered in Seinäjoki, Finland. As of the end of 2020, the Company had 28 full-time employees and its total revenue for the full year ended December 31st, 2020 was EUR 2.86m. Growth has accelerated in 2021 and extract sales reached EUR 1.9m in the period 1st January – 31st March, corresponding to 560 percent sales growth compared to the same period prior year.

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEELAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, DISTRIBUTION OR RELEASE WOULD BE IN CONFLICT WITH APPLICABLE RULES OR REQUIRE ADDITIONAL REGISTRATION OR OTHER ACTIONS.
 

Provided by: Cision
Spotlight Stock Market (Sweden)
Eevia Health Oyj
Eevia is a life science company focused on manufacturing and selling health-promoting natural ingredients derived from the Arctic region’s raw materials....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More